Cita APA

Vallez-Valero, L., Gasó-Gago, I., Marcos Fendian, Á., Garrido-Alejos, G., Riera-Magallón, A., Plaza Díaz, A., . . . Corominas, H. (2023). Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.

Citación estilo Chicago

Vallez-Valero, Lucía|||0000-0001-9163-302X, Ingrid Gasó-Gago, Ángel|||0000-0003-2595-5906 Marcos Fendian, Gemma|||0000-0001-8249-2771 Garrido-Alejos, Adrià Riera-Magallón, Adrián|||0000-0002-5316-5090 Plaza Díaz, Cristina|||0000-0001-5079-613X Martinez-Molina, Maria Antònia Mangues-Bafalluy, y Hèctor|||0000-0002-7738-6787 Corominas. Are All JAK Inhibitors for the Treatment of Rheumatoid Arthritis Equivalent? An Adjusted Indirect Comparison of the Efficacy of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib. 2023.

Cita MLA

Vallez-Valero, Lucía|||0000-0001-9163-302X, et al. Are All JAK Inhibitors for the Treatment of Rheumatoid Arthritis Equivalent? An Adjusted Indirect Comparison of the Efficacy of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib. 2023.